AKT1 and breast carcinoma: Blocking the PI3K/Akt/mTOR pathway enhances the radiation response of breast cancer models in vitro (187), and phase II clinical trials have shown that CCI-779, an mTOR inhibitor, is an effective treatment for breast cancer (188).